University of Rochester Medical Center, Rochester, New York 14642, USA.
Clin Cancer Res. 2011 Oct 1;17(19):6112-7. doi: 10.1158/1078-0432.CCR-11-1073. Epub 2011 Aug 15.
Gene expression profiling has had a major impact on our understanding of the biology and heterogeneity of diffuse large B-cell lymphoma (DLBCL). Using this technology, investigators can identify biologic subgroups of DLBCL that provide unique targets for rational therapeutic intervention. This review summarizes these potential targets and updates the progress of clinical development of exciting novel agents for the treatment of DLBCL. Results of ongoing studies suggest that in the near future, we will be able to use gene expression profiling, or an accurate surrogate, to define the best therapeutic approach for individual patients with DLBCL.
基因表达谱分析对我们理解弥漫性大 B 细胞淋巴瘤（DLBCL）的生物学和异质性产生了重大影响。利用这项技术，研究人员可以鉴定出 DLBCL 的生物学亚群，为合理的治疗干预提供独特的靶点。这篇综述总结了这些潜在的靶点，并更新了治疗 DLBCL 的新型药物的临床开发进展。正在进行的研究结果表明，在不久的将来，我们将能够使用基因表达谱分析或准确的替代物来为每个 DLBCL 患者定义最佳的治疗方法。
